Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 3/20 | 0.40 |
| ▸ | PPARA | Q07869 | 3/20 | 0.40 |
| ▸ | ACE | P12821 | 3/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.37 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.37 |
| ▸ | PPARD | Q03181 | 2/20 | 0.37 |
| ▸ | CES1 | P23141 | 2/20 | 0.37 |
| ▸ | METAP2 | P50579 | 1/20 | 0.36 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.36 |
| ▸ | CPA1 | P15085 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8311399 | 0.85 | PPARA (0.37) | PPARGPPARAACECYP2C19PPARD | |
| SCHEMBL8922764 | 0.84 | PPARG (0.42) | PPARGPPARAACECYP2C19PPARD | |
| SCHEMBL14640210 | 0.72 | CPA1 (0.44) | ACECYP2C19CES1CPA1 | |
| SCHEMBL8314036 | 0.72 | PPARA (0.36) | PPARGPPARAACECYP2C19PPARD | |
| SCHEMBL8310840 | 0.71 | PPARA (0.42) | PPARGPPARAACECYP2C19PPARD | |
| SCHEMBL18270379 | 0.70 | PPARA (0.47) | PPARGPPARAACECYP2C19 | |
| SCHEMBL4983034 | 0.70 | PPARA (0.47) | PPARGPPARAACECYP2C19 | |
| SCHEMBL10420288 | 0.70 | MEN1 (0.43) | CYP2C19CES1RIPK1CPA1 | |
| SCHEMBL10420286 | 0.70 | MEN1 (0.43) | CYP2C19CES1RIPK1CPA1 | |
| SCHEMBL8310839 | 0.69 | ACE (0.42) | PPARGPPARAACECYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2064202-A2 | A NEW CRYSTALLINE FORM G OF (5S)-5-[4-(5-CHLORO-PYRIDIN-2-YLOXY)-PIPERIDINE-1-SULFONYL-METHYL]-5-METHYL-IMIDAZOLIDINE-2,4-DIONE (I) AND INTERMEDIATES THEREOF. | AstraZeneca AB (SE) | 2009-06-03 | — | — | EP | disclosed |
| WO-2007106022-A2 | A NEW CRYSTALLINE FORM G OF (5S) -5- [4- (5-CHLORO-PYRIDIN-2- YLOXY) -PIPERIDINE-1-SULFONYLMETHYL] - 5 -METHYL -IMIDAZOLIDINE - 2,4-DIONE (I) AND INTERMEDIATES THEREOF. | ASTRAZENECA AB (SE) | 2007-09-20 | — | — | WO | disclosed |